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The development of a group B Streptococcus (GBS) vaccine for maternal immunization constitutes a global
public health priority, to prevent GBS-associated early life invasive disease, stillbirth, premature birth,
maternal sepsis, adverse neurodevelopmental consequences, and to reduce perinatal antibiotic use.
Sample size requirements for the conduct of a randomized placebo-controlled trial to assess vaccine effi-
cacy against themost relevant clinical endpoints, under conditions of appropriate ethical standards of care,
constitute a significant obstacle on the pathway to vaccine availability. Alternatively, indirect evidence of
protection based on immunologic data from vaccine and sero-epidemiological studies, complemented by
data fromopsonophagocytic in vitro assays andanimalmodels, couldbe considered aspivotal data for licen-
sure, with subsequent confirmation of effectiveness against disease outcomes in post-licensure evalua-
tions. Based on discussions initiated by the World Health Organization we present key considerations
about the potential role of correlates of protection towards an accelerated pathway for GBS vaccine licen-
sure andwide scale use. Priority activities to support progress to regulatory andpolicydecision are outlined.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
1.1. Burden
Group B Streptococcus (GBS) is a leading cause of maternal, foe-
tal, neonatal and young infant invasive bacterial disease. According
to recent global disease burden estimates, GBS causes 319,000
cases of early life invasive bacterial disease and 90,000 infant
deaths annually. While data gaps hinder precise estimates for
other disease syndromes, a conservative assessment suggests thatecision
s://doi.
2 J. Vekemans et al. / Vaccine xxx (xxxx) xxxyearly, 57,000 stillbirths are caused by GBS and 33,000 pregnant or
puerperal women have GBS sepsis. There is also a significant,
unquantified burden of GBS-related prematurity, neurodevelop-
mental impairment and maternal deaths. The African continent
accounts for an estimated 54% of cases of GBS invasive disease
and 65% of all foetal/infant GBS deaths [1].
The reservoir for GBS in humans is the gastrointestinal tract,
and maternal recto-vaginal colonization can lead to ascending foe-
tal infection, stillbirth and early onset neonatal sepsis. Maternal
colonization in pregnancy (ranging from about 10% to 40%) has
been found in women in all geographical settings evaluated [2].
Although incidence is highest during the first days of life, the risk
of GBS disease in young infants extends to 3 months of life. Intra-
partum antibiotic prophylaxis (IAP), guided by microbiological or
clinical screening strategies, has been shown to reduce the risk of
early-onset GBS disease (EOD, days 0–6 after birth) in some high-
income settings, but has shown no impact on late-onset GBS dis-
ease (LOD, days 7–89) and does not prevent GBS-associated still-
births and prematurity. There are considerable challenges to
implementing effective IAP-based prevention strategies, especially
in resource-limited settings, and there are concerns about unin-
tended consequences of neonatal antibiotic exposure, including
its impact on the gut microbiome and in contributing to the gener-
ation of antibiotic resistance [3].
1.2. Vaccine landscape
A summary of the GBS vaccine development landscape is pre-
sented in Panel 1. The development of GBS vaccines suitable for
immunization during pregnancy has been identified as a priority
by the World Health Organization (WHO), and key consensus doc-
uments presenting preferences for GBS vaccine product character-
istics and a research and development technology roadmap have
been developed [10]. Consensus-building about a preferred clinical
development pathway and defining the pivotal data package
requirement for licensure, and policy for vaccine use, were high-
lighted as priority activities.Pl
an
orPanel 1 Vaccine candidate landscape Two large pharma-
ceutical companies, GlaxoSmithKline (GSK) and Pfizer, are
building on their experience in polysaccharide-protein conju-
gation technology to develop GBS vaccines. Ten GBS capsu-
lar envelope polysaccharide (CPS)-based serotypes have
been described, however, the majority of invasive disease
in young infants is caused by a few of these serotypes (pre-
dominantly Ia, Ib, II, III, IV, V) [4]. Both companies have devel-
oped candidate vaccines targeting the major serotypes
associated with neonatal disease, using the CRM197 diphthe-
ria protein for conjugation. Novartis, which has been
acquired by GSK, developed a trivalent conjugate vaccine
(Ia, Ib, III), which showed favourable safety and immuno-
genicity in phase I and II studies in non-pregnant and preg-
nant women [5]. Opsonophagocytic bacterial killing activity
in umbilical cord sera, correlating with serotype-specific IgG
antibody concentrations, and functional activity in a mouse
bacterial challenge model, were demonstrated [6]. Unde-
tectable serotype-specific capsular antibodies at baseline
and maternal HIV infection were, however, associated with
reduced immunogenicity [7]. Vaccination in pregnancy was
shown not to inhibit offspring responses to recommended
vaccines comprised of CRM197-based conjugates [8]. GSK
is back to preclinical, reformulating the candidate vaccine,
while Pfizer is developing a hexavalent formulation (Ia, Ib,
II, III, IV, V). A Phase I/2 clinical study in the US has been com-
pleted in healthy adults (NCT03170609) and a trial in pregnant
women in South Africa, co-funded by the Bill and Melinda
Gates Foundation (BMGF), isbeing initiated (NCT03765073).ease cite this article as: J. Vekemans, J. Crofts, C. J. Baker et al., The role of im
d use of group B Streptococcus vaccines for maternal immunization: consider
g/10.1016/j.vaccine.2019.04.039A BMGF-funded partnership has also been announced
between PATH and The Biovac Institute, a South-African
government-private partnership, aimed at developing in-
country manufacturing capacity. This vaccine development
programme will aim for the development of a low-cost conju-
gate GBS vaccine against serotypes causing >90% of invasive
GBS disease in Africa.
Minervax, in contrast, is developing a protein-based GBS
vaccine, targeting the N-terminal domains of the
Alp-protein family. The induction of functional activity and
protection from protein-based GBS vaccines have been
investigated in preclinical infection models, and further
sero-epidemiological studies are required to confirm whether
immunity targeting these proteins derived from natural expo-
sure is associated with protection against early life invasive
disease [9]. Minervax has completed a phase 1 trial in non-
pregnant women 18–40 years of age (NCT02459262) but
results have not been published to date. Another Phase 1 trial
is ongoing (NCT03807245).1.3. Randomized controlled vaccine clinical efficacy trial: a sample size
challenge
The conduct of double-blind placebo-controlled randomized tri-
als to assess vaccine efficacy against clinically relevant,
pre-defined, endpoints constitutes the gold-standard approach to
generate evidence for vaccine licensure and policy decisions. How-
ever, a pivotal GBS vaccine efficacy trial would require a very large
sample size, as shown in Table 1. Baseline incidences of invasive
GBS disease of 1–3 events per 1000 live births have been reported
in some low-resources settings [3], but baseline incidence in a trial
will depend on standards of care and subject selection criteria. In a
trial, ethical considerations would require implementation of
national and non GBS-specific WHO recommendations for infec-
tion prevention and strengthening of access to pre- and peri-
natal care, ensuring appropriate medical oversight of delivery
and prescription of intrapartum antibiotics in the presence of
infectious risk factors, which would reduce baseline attack rates.
It seems unlikely that the baseline incidence of eligible endpoint
cases would be much higher than 0.5–1 per 1000 live births, for
a trial conducted in the context of fully implemented local health-
care guidelines and optimal access to care. Candidate vaccines
against other pathogens have been tested in very large pivotal tri-
als before, but specificities related to GBS, including vaccination of
women during pregnancy, the extremely rapid progression of GBS
sepsis before and soon after birth, follow up requirements for
women in late pregnancy, for babies in the first days and weeks
of life, the need to investigate stillbirth and fatal cases, the needs
for adequate safety oversight and efficacy monitoring requiring
invasive sampling (blood and CSF) and bacteriologic analyses
would make such a GBS vaccine trial with clinical endpoints
lengthy and very costly. This traditional clinical development path-
way would constitute a potential major obstacle to progress
towards availability of a much-needed vaccine.
1.4. Alternative pathway via correlates of protection
If a pre-licensure pivotal randomized controlled clinical efficacy
trial is not possible, on grounds of cost or feasibility, alternative
strategies to support licensure need to be considered. The aim of
this report is to highlight the potential role that immune correlates
of protection may have for an accelerated GBS vaccine develop-
ment pathway to licensure and policy decision. Related, prioritymune correlates of protection on the pathway to licensure, policy decision
ations from World Health Organization consultations, Vaccine, https://doi.
Table 2
The role of immune correlates of protection: key activities on an accelerated pathway to GBS vaccine licensure, policy decision and global use.
1. Networks of investigators able to deliver high quality data according to Good Clinical Practices are developed, including research centres from diverse geographical
areas. Baseline data are collected, supporting detailed epidemiological characterization and preparing for high standards in data collection and study procedures.
Clinical management algorithms and standards of care are defined.
2. High quality standardized functional immune assays, measuring bactericidal activity in serum, are developed; antigen binding assays that closely correlate with
functional activity are developed.
3. Study protocols aimed at characterizing the relationship between antibody concentrations and disease risk in a non-vaccinated, naturally exposed population, are
developed.
4. Detailed analysis plans based on threshold or continuous model analysis are pre-established, defining the primary analysis and secondary exploratory analyses.
Sample timepoints of analysis are predefined. Specific and sensitive clinically relevant endpoints are pre-defined.
5. Large-scale sero-epidemiological studies are conducted across diverse geographical settings, designed specifically to support derivation of correlates of protection.
6. Estimates of effects on the protective function of antibodies are produced, according to predefined analytical plans. When possible, serotype/strain specific esti-
mates of effects are produced. Factors affecting the association are characterized. Aggregate estimates across serotypes/strains are generated.
7. Maternal vaccination trials are conducted according to predefined protocols and analytical plans.
8. Favourable safety is established, to international quality standards.
9. Success criteria are pre-defined: vaccination induces antibody levels above protective thresholds in a high, predefined proportion of recipients (or alternative robust
statistical estimates based on continuous models). Aggregate estimates of effects are produced, serotype/strain specificity is investigated. Antibody persistence is
demonstrated, beyond the period-at-risk. Pre-defined success criteria are passed.
10. Factors affecting immunogenicity and antibody transfer are characterized.
11. Vaccine induced antibodies are shown to be functionally active in bactericidal assays. Serotype/strain specificity is investigated.
12. Various animal models of protection suggest vaccination protects against experimental infection. Serotype/strain specificity is investigated.
13. Initial licensure is obtained based on indirect evidence and agreement on necessary post-licensure Phase 4 effectiveness studies
14. Plans for confirmatory evaluation of public health impact based on consensus study design are developed early and financed.
15. Post-licensure pilot implementation studies are conducted without delays, leading to policy decision for wide-scale use, country processes start, and procurement
is ensured by public health agencies, informed by implementation science and analyses of full public vaccine value.
Table 1
Total number of pregnant women required in a placebo-controlled trial to demonstrate the efficacy of a GBS vaccine candidate against a defined disease endpoint.
Vaccine efficacy trial is designed to detect
(with a lower limit of 95% confidence interval of 25%)
Expected disease rate in placebo recipients (cases per 1000 livebirths)
2.0 1.0 0.5 0.1
80% 30,000 62,000 122,000 620,000
60% 90,000 180,000 360,000 1,804,000
Note: Method according to Farrington, 1990 [11].
Assumptions: 80% power, P < 0.05 for significance, 1:1 vaccine:placebo allocation, 15% loss to follow-up, 90% cases eligibility for inclusion as per primary case definition, 95%
matching between vaccine and circulating types.
J. Vekemans et al. / Vaccine xxx (xxxx) xxx 3activities to are outlined in Table 2. The considerations presented
here were informed by a consensus-generating consultation pro-
cess that started with a meeting of experts and specific stake-
holders, organized by WHO in London on Dec 16th, 2017, and
further iterative exchanges with experts and stakeholders in the
field. These considerations aim to inform vaccine development
strategies, complementing recent discussions in other fora,
including those organized by the US Food and Drug Administra-
tion and the UK Joint Committee on Vaccination and Immuniza-
tion [12,13].
General WHO considerations on methods leading to definitions
of correlates of vaccine-induced protection have been presented
elsewhere [14]. Accordingly, in terms of nomenclature, we here
refer to a substitute endpoint as a non-clinical pivotal endpoint
which may be used to support licensing decisions, and to immune
correlates of protection as immune markers shown to correlate
statistically with a reduced risk of disease. Such a correlate may,
or may not, be a causal mediator of protection. The term ‘surrogate
endpoint’, specifically implies that the measured marker is a cau-
sal, mechanistic mediator of protection.
1.5. Past experience on the role of correlates of protection on the
pathway to vaccine availability
Correlates of protection have played an important role in sup-
porting the licensure of several conjugated vaccines targeting
encapsulated bacteria [15,16], as reviewed in Panel 2. The type of
studies that have contributed to establishing evidence of correlatesPlease cite this article as: J. Vekemans, J. Crofts, C. J. Baker et al., The role of im
and use of group B Streptococcus vaccines for maternal immunization: consider
org/10.1016/j.vaccine.2019.04.039of protection have included sero-epidemiological studies, showing
associations between antibody levels and subsequent incidence of
disease, passive immunization experiments with serum transfer in
animal models or humans showing protection; animal models of
vaccine-induced protection; in vitro bacterial killing assays; and
ultimately human efficacy, effectiveness studies.
When putting into perspective past experience with other
vaccines and considerations on substitute immunological end-
points for GBS, important similarities and differences can be
highlighted. Often, the mechanism of immunity derived from
natural exposure and vaccine-induced immunity is similar, and
based on functional antibodies, but protective thresholds can
differ according to antibody qualitative characteristics. Thresh-
olds may also vary by pathogen strain/serotype and clinical
syndrome. In all the non-GBS examples discussed in Panel 2,
some efficacy data were part of the evidence package used for
licensure, although not necessarily specific to all antigens
included in the vaccine. Sometimes the efficacy evidence was
derived by analogy to a related vaccine rather than generated
from the candidate vaccine itself. Relative to other diseases
with extended time-at-risk, the time window of susceptibility
to invasive GBS disease in babies is narrow, which should allow
a more specific evaluation of the relationship between antibody
threshold and protection over time. Another important differ-
ence relates to the fact that adaptive immunity in babies is
not expected to play a role in early life protection against
GBS, as protection would be passively derived only from acqui-
sition of maternal antibodies.mune correlates of protection on the pathway to licensure, policy decision
ations from World Health Organization consultations, Vaccine, https://doi.
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Pl
an
orPanel 2 Learning from history: The role of correlates of
protection on the development pathway of selected available
vaccines As early as 1933, epidemiological studies of
Haemophilus influenzae type b (Hib) infections showed that
serum bactericidal activity (SBA) increased with age [17].
SBAwas later found to be correlatedwith the level of IgG anti-
body against the organism’s CPS, allowing serum ELISA con-
centrations to be considered as a useful marker associated
with protection [18]. Subsequent efficacy studies of a Hib
polysaccharide vaccine candidate led to the demonstration
of an association between vaccine-induced antibodies and
protection from natural Hib exposure, and the definition of
protective thresholds [19]. CPS conjugation with a carrier pro-
tein increased immunogenicity and functional activity in vitro,
and a lower antibody threshold of protection than for the
polysaccharide vaccine. Post-immunization with a protein
conjugate Hib CPS vaccine, a peak antibody concentration
of 1 lg/mL is considered as a marker of long-term protection.
Prevalent concentrations above 0.15 lg/mL are considered as
protective against Hib bacteraemia and are accepted as such
by regulators for licensure of new vaccines or for bridging
studies [15]. Higher levels of antibodies have been associated
with protection against nasopharyngeal carriage [20].
Epidemiological studies in the 19600s similarly showed an
association between age and anti-capsular groups A, B and C
meningococcus serum complement-dependent bactericidal
assay (SBA), and between the latter and the risk of meningitis
[21]. Vaccine efficacy trials leading to licensure and introduc-
tion of polysaccharide meningococcal A and A/C vaccines
enabled correlate of protection to be defined. Quadrivalent
formulations, including serogroups W and Y in addition to
A and C, were marketed internationally with no direct evi-
dence of efficacy for the W and Y serotypes. Serological crite-
ria alone without direct evidence of efficacy supported the
introduction of the meningococcal C conjugate vaccine in
the United Kingdom in 1999, and it was only when early
post-licensure evaluation produced efficacy estimates that
the licensure criteria were clinically validated [22]. A ser-
ogroup A meningococcal polysaccharide-tetanus toxoid con-
jugate vaccine was licensed in India in 2009, and pre-qualified
by WHO in 2010, on safety and immunogenicity (SBA assays)
data only. The vaccine was then deployed in the sub-Saharan
Africa meningitis belt and shown to be protective against
meningococcal meningitis [23].
More recently, a non-capsular, outer membrane protein
(OMP)-based meningococcal group B vaccine was licensed,
based on indirect evidence of efficacy. Vaccine efficacy had
been demonstrated in the 1990s for two OMP-based vaccines
derived from outer membrane vesicles (OMV), and the asso-
ciation with hSBA responses (h indicative of human comple-
ment use) had been shown [24]. However, the highly variable
nature of the immunodominant vesicular PorA protein lim-
ited strain coverage, and genomic advances in the 20000s
supported the development of new protein vaccine candi-
dates. In 2013, MenB-4C was licensed in Europe, based on
demonstrated SBA against a panel of strains matched to
the vaccine antigens in the absence of direct efficacy data.
In 2015, MenB-4C was introduced in the routine infant vacci-
nation schedule in the UK. In 2015, the MenB-FHbp and
MenB-4C protein vaccines were licensed by the US FDA,
based on regulations for accelerated approval, which sup-
ports approval of vaccines for serious or life-threatening dis-
eases based on safety and indirect evidence reasonably likely
to predict clinical benefit, in this case hSBA responses. As a
requirement, post-marketing confirmatory effectiveness
studies were to be conducted, including investigating herd
protection and evaluating the impact of vaccination on strain
variation and carriage [25]. Post-licensure evidence of effec-
tiveness soon emerged [26].ease cite this article as: J. Vekemans, J. Crofts, C. J. Baker et al., The role of im
d use of group B Streptococcus vaccines for maternal immunization: consider
g/10.1016/j.vaccine.2019.04.039Randomized controlled trials initially established the
protective efficacy of the 7-valent pneumococcal conjugate
vaccine (PCV), which allowed the derivation of serotype-
specific serum antibody protective thresholds for some sero-
types, but not for the less common ones. Although there was
no evidence demonstrating that protective thresholds were
the same for different serotypes, it was considered accept-
able to estimate an aggregate threshold through data pool-
ing, serving as target for all serotypes [27]. The aggregate
threshold was used for licensure of subsequent PCV vacci-
nes, using head-to-head immunogenicity studies for the
same serotypes, and as a stand-alone reference for the addi-
tional serotypes when new capsular types were included.
Post-licensure, serotype-specific protective thresholds docu-
mented from vaccine effectiveness studies showed some
variation relative to the initially inferred aggregate correlate
of protection [28].
Correlates of protection were initially established in effi-
cacy studies of PCV against all invasive pneumococcal dis-
ease (including bacteraemia and meningitis), but true
threshold might differ according to disease entities. Protec-
tive levels associated with protection against acute otitis
media may be higher [29]. Results from a study of
maternal-foetal transfer of antibodies acquired following nat-
ural exposure suggested that even higher antibody levels are
needed to prevent pneumococcal carriage in infants [30].2. Establishing a valid correlate of protection for the licensure
of GBS vaccines: available evidence, ongoing studies
2.1. Current evidence base
The first suggestion that it may be possible to establish a sero-
logical correlate of protection for GBS was presented four decades
ago [31]. A number of studies have since reported a reduced risk of
invasive disease in neonates and young infants associated with
higher maternal antibodies acquired following natural exposure
[32–37], as presented in a recent review [38]. In most studies,
ligand-binding or Luminex assays were used; in some,
opsonophagocytic in vitro killing assays were used. While
antibody-mediated risk reduction estimates have been reported
from different studies for the most frequent serotypes (Ia, III, V),
rigorous estimates of protective thresholds have not been estab-
lished. There were important differences in the design of the vari-
ous studies, which were conducted across diverse populations and
epidemiological settings, with different standards of care, studying
different target antigens, using different reference sera and other
control reagents, assay methodologies, analytical methods, and
length of follow-up. An inverse association between levels of anti-
bodies and neonatal risk of invasive disease has also been shown
for some protein candidate antigens, but not others [37,39,40]. In
addition, other studies aiming to characterize correlates of protec-
tion are currently underway or being planned.
2.2. Ongoing or planned sero-epidemiology studies
In South Africa, a prospective, observational cohort of 35,000
mother-newborn pairs was enrolled between 2015 and 2017.
Enrolment was re-initiated in 2019, to include a further 15,000
pairs. Infants were followed-up by hospital-based surveillance for
invasive GBS disease. In parallel, infants with invasive disease that
were not enrolled into the birth cohort were, and will further be,
identified across multiple hospitals. The study aims to be poweredmune correlates of protection on the pathway to licensure, policy decision
ations from World Health Organization consultations, Vaccine, https://doi.
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serotype Ia and III, the most common serotypes causing invasive
disease in South Africa. Cases will be matched to controls for
maternal colonization status with a homotypic serotype during
labour, maternal age, birth weight, newborn gender and maternal
HIV status (Shabir Madhi, personal communication).
A case-control study with similar objectives is also planned in
the United States by the Centers for Disease Control and Prevention
(CDC). The association between GBS serotype-specific capsular IgG
antibody concentrations at birth and odds of invasive GBS disease
will be estimated, for serotypes Ia and III separately. Cases will be
identified in 2019–2022 from CDC’s Active Bacterial Core surveil-
lance program. Controls will be babies of GBS-colonized mothers
identified at participating clinical centres performing routine ante-
natal screening for GBS colonization. Remainders of the newborn
screening dried blood spot (DBS) samples will be used for antibody
measurements. The study aims to enrol approximately 500 cases
and 3000 controls (Stephanie Schrag, personal communication).
Pilot studies are underway both in the UK and Uganda to assess
the feasibility of prospectively enrolling a high number of mother-
infant pairs and collect maternal and cord sera (150.000 in the UK,
35.000 in Uganda), using similar methodologies. All pairs are
planned to be followed up to 90 days after birth. In case of disease,
another maternal and infant sample will be taken and antibody
titres compared to those at birth. Controls will be selected from
both GBS-colonized and GBS non-colonized women matched on
gestation and gender, aiming for at least 3 controls for every case.
A further retrospective study from 2014, based on stored DBS sam-
ples, is also underway, using serum samples from 150 cases and
three times as many controls (Kirsty Le Doare, personal
communication).2.3. Animal models
In addition to sero-epidemiological studies, studies in relevant
experimental animal models can contribute to establishing evi-
dence of a protective role of antibodies induced by vaccination.
Such models have provided useful mechanistic insights into the
pathogenesis and the impact of antibody-mediated responses on
GBS disease. Passive transfer of antibodies targeting the polysac-
charide envelope has provided serotype-specific protection from
experimental GBS challenge [41]. Passive transfer of antibodies
acquired following experimental infection has also been shown
to be partially protective in rhesus monkeys [42]. Animal models
have also been used to study the protective effect of maternal
immunisation on the offspring and have demonstrated placental
antibody transfer and favourable outcomes, for both capsular
envelope polysaccharide and protein-based candidate vaccines
[37,43,44]. Maternal vaccination in non-human primate models
has been shown to induce high maternal antibodies and results
in transfer of functional antibodies to offspring [45].3. Defining the way forward
Upon demonstration that a traditional clinical development
pathway is unfeasible at a reasonable cost, alternative approaches
should be considered. Whatever the approach, strong evidence
establishing the validity of substitute endpoint(s) as reliable pre-
dictors of clinical benefit will be required to support regulatory
and policy decisions. Important consensus recommendations
about the use of an immunological substitute endpoint are high-
lighted here, and an analysis framework for critical appraisal of
evidence is presented in Panel 3.Please cite this article as: J. Vekemans, J. Crofts, C. J. Baker et al., The role of im
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tute endpoint The most important determining factor for
the accelerated approval of a GBS vaccine based on a non-
clinical endpoint will be how strongly the available package
of evidence is graded as reasonably likely to predict clinical
benefit.
The Prentice criteria have been proposed to assess the
validity of proposed substitute endpoints [46]. The first
requirement is that vaccination affects outcome. The pro-
posed accelerated approval pathway assumes that this can
only be inferred indirectly and cannot be demonstrated pre-
licensure and should be demonstrated after initial vaccine
introduction. The second criterion is that vaccination affects
surrogates (in this case antibodies), which can be demon-
strated in vaccine immunogenicity studies. The third criterion
is that surrogates affect outcome. This would need to be
established in sero-epidemiological studies. The fourth crite-
rion is that the conditional disease risk (the association
between the surrogate outcome and the disease risk) is the
same in vaccinated and unvaccinated individuals. The full
mediation condition relates to the observation that the sub-
stitute variable is a full mediator of protection. In this situa-
tion, whereby we want to extrapolate results from
immunity studies in conditions of natural exposure with
immunity resulting from vaccination, this assumes that the
protective mechanism is the same in both conditions (non-
vaccinated previously exposed and vaccinated), or is suffi-
ciently close. This relies on the assumption that functionality
of antibodies induced by vaccination and natural exposure
are the same (or closely associated). Assessing this requires
an understanding of the underlying biological mechanism,
and a causality assessment of the link between the substitute
endpoint and the clinical endpoint of ultimate interest.
The Bradford-Hill criteria have been proposed to support
causality assessments: 1. Temporal sequence of association
(exposure triggers appearance of antibodies, the role of
which precede the clinical outcome); 2. Strength of associa-
tion (to be determined in sero-epidemiological studies); 3.
Consistency of association (shown through repeat studies
in different settings); 4. Biological gradient (as to be deter-
mined in sero-epidemiological studies); 5. Specificity (a criti-
cal criteria, as other trans-placentally transferred protective
immune effectors that are not induced by vaccination could
lead to an over-estimate of the potential impact of vaccines);
6. Plausibility (supported by other maternal immunization
platforms and by other vaccines targeting encapsulated bac-
teria); 7. Coherence (the causality assumption does not
appear to conflict with current knowledge); 8. Experimental
reversibility (upon waning of immunity acquired post expo-
sure); 9. Analogy (supported by other maternal immunization
platforms and by other vaccines targeting encapsulated
bacteria).
Based on this analysis framework, a functional antibody
assay would seem preferable as a scientifically justifiable
substitute endpoint to just a quantitative, non-functional
antigen-binding assay. Alternatively, strong evidence of the
correspondence between functional and non-functional
quantitative assays should be demonstrated. Animal models
of vaccine-induced protection would also add to the evidence
that the measured antibodies are clinically relevant.3.1. Safety
The safety evaluation of a candidate vaccine needs to be at least
as rigorous as that required for vaccines licensed by traditional
clinical development pathways. When considering risk-benefit,
the uncertainty about the benefit derived using a substitutemune correlates of protection on the pathway to licensure, policy decision
ations from World Health Organization consultations, Vaccine, https://doi.
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expectation. Considerations about pregnancy immunization safety
characterization are presented elsewhere [47].
3.2. Endpoint case definitions
Standard case definitions and ascertainment methodologies are
needed to produce clinically relevant estimates of effect for both
the evaluation of vaccine efficacy against a clinical endpoint, and
for the evaluation of association between antibody levels and clin-
ical outcomes in a sero-epidemiologic study. WHO preferred case
definitions and ascertainment methodologies are described else-
where [48]. Briefly, a systematic case detection system should be
implemented to support identification of confirmed GBS cases.
The use of a composite endpoint, including different clinically rel-
evant disease entities (e.g., GBS-confirmed stillbirth, EOD, LOD, and
fatal invasive disease) may need to be considered to reduce study
size requirements. Case detection systems need to be applied from
late pregnancy or at the time of birth, as most cases of EOD occur
on the day of birth. The clinical management algorithm and clinical
criteria used to trigger collection of a clinical sample for GBS cul-
ture will play a critical role in identifying cases. Criteria used to
trigger sample collection should be set to maximize case capture.
Highest standards of sterile technique in sample collection should
be applied, to avoid sample bacterial contamination and maximize
sensitivity, which is drastically reduced if an insufficient blood vol-
ume is collected.
The role of GBS maternal or neonatal colonization as a potential
substitute endpoint has been discussed elsewhere and is outside
the scope of this report [48]. In the context of a sero-
epidemiological study to define serological correlates of protection,
detection of maternal recto-vaginal colonization and neonatal col-
onization and bacterial typing is encouraged, as a secondary strat-
ified analysis considering colonization status may contribute to
data interpretation.
3.3. Assay quality systems
High quality standards in assay quantification of antibody level
and function should apply. Characterization of the performance of
the assay need to be adapted to the vaccine development status,
noting that an immunological substitute endpoint should ulti-
mately be based on fully analytically validated assays. Interna-
tional agreement on standards and methodologies will provide
the necessary support for comparison and bridging studies. A col-
laborative initiative towards the development of validated stan-
dardized immunoassays is ongoing [49].
3.4. Sampling timepoints
The choice of sampling timepoints in both mothers and off-
spring will be a key determinant of the evaluation of the associa-
tion between antibody levels and protection. Samples from both
the mother and the offspring should be analysed. Several options
could be considered to define the primary time-point used to
assess protection thresholds. The analysis of a maternal post-
immunization serum sample may constitute a pragmatic approach
to capture an overall target level that would be associated with a
reduction of the overall risk of adverse outcomes, including still-
birth, maternal and infant outcomes. However, sources of hetero-
geneity need to be considered, as the gestational age at
vaccination, prematurity and co-morbidities affect placental trans-
fer of antibodies. Thresholds may also vary according to clinical
outcomes considered. Antibody levels in cord blood provide an
opportunity to define, possibly with more specificity and precision,
a functional protective antibody threshold – the level of antibodiesPlease cite this article as: J. Vekemans, J. Crofts, C. J. Baker et al., The role of im
and use of group B Streptococcus vaccines for maternal immunization: consider
org/10.1016/j.vaccine.2019.04.039that is required to prevent invasive disease in the offspring, upon
initial bacterial penetration into the blood stream. Further research
is necessary to understand whether neonatal antibody levels mea-
sured may be lowered, in the context of invasive infection, by bac-
terial binding of antibody, and implications for data interpretation.
The characterization of antibody persistence over time up to the
end of the at-risk period may also contribute to assess the relation-
ship between antibody levels and disease risk, especially for late-
onset disease.
In vaccine studies, antibody levels at birth should be evaluated
as a function of timing of maternal immunization during preg-
nancy, for vaccination program planning.
3.5. Statistical considerations
Important statistical considerations driving the prospective
development of analysis plans need to be defined. WHO has
expressed a preference for an 80% level of protection provided by
GBS vaccination [10], and this should guide sample size determina-
tion for an approach using immune correlates of protection. The
target effect size and a detailed analysis plan defining the primary
outcome of interest and key secondary analyses should be prospec-
tively defined. The respective advantages and limitations of various
statistical analysis methodologies should be considered. Whether a
threshold or continuous model-based approach is favoured should
be predefined [50].
Geographical heterogeneities should be considered, as the pro-
tective threshold may differ according to various host and patho-
gen factors. Statistical evaluations should also be undertaken in
consideration of other variables that may impact the validity of
the assumptions. The number, intensity and duration of prior
GBS infections, comorbidities, the microbiome, host genetics, or
pathogen characteristics may impact the type of immune response
generated after natural infection as compared to a response
to vaccination, with potential consequences on antibody transfer.
Statistical models supporting the assessment of the role of multiple
variables may contribute to a better characterization of the
strength of the assumptions. Exploratory evaluations can
contribute to characterize the role of phenotypic and genotypic dif-
ferences in the pathogen with protection, thereby producing valu-
able knowledge to inform vaccine development pathways and
decision-making.
If the vaccine-induced antibody levels are far above the anti-
body protective threshold defined by studies in conditions of nat-
ural exposure, the likelihood that the vaccine is protective will be
higher. A risk management plan should be considered if a signifi-
cant proportion of vaccinated individuals are categorized as low
responders, which may justify investigating a two-dose vaccine
regimen, possibly including a pre-pregnancy priming dose.
A concern, regarding the validity of extrapolating a threshold
indicative of antibody-mediated immunity resulting from natural
exposure to post vaccination levels, relates to the possibility that
other protective immune mediators, activated by natural exposure
(ie antibodies targeting other antigens), are transferred to the foe-
tus, but may not be induced by vaccination. In theory, this effect
could be complete, or only partial, if the measured antibody is just
one mediator of protection amongst others. Such a situation may
lead to an overestimation of the likely vaccine efficacy based on
the substitute immunological endpoint. A way to mitigate this con-
cern would be to build a strong data package indicative of the
direct protective role of the substitute immune endpoint effector
(i.e., ideally establishing that the immune response is both neces-
sary and sufficient for protection), or of the close association
between the measured endpoint and the causal mediator of pro-
tection. For instance, confidence in the extrapolation of immunity
from natural exposure to immunity resulting from vaccinationmune correlates of protection on the pathway to licensure, policy decision
ations from World Health Organization consultations, Vaccine, https://doi.
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body is functional, through measurement of bacterial killing
assays, and by animal models of protection.3.6. Rare serotypes
Even if it were possible to conduct a large randomized con-
trolled trial testing the efficacy of a multivalent polysaccharide-
protein conjugate candidate vaccine, such a trial may generate an
overall vaccine efficacy estimate, and possibly serotype-specific
efficacy estimates for the most frequent serotypes. It is unlikely
that reliable vaccine efficacy estimates would be produced for less
common serotypes. Similarly, epidemiological studies in condi-
tions of natural exposure may generate estimates of protective
serological thresholds against the most frequent serotypes, but
not the less common ones. As has been done for other multivalent
vaccines, an aggregate threshold may need to be derived, based on
a weighted average, observations about threshold differences
across common serotypes and some plausible assumptions. Later,
subsequent post-licensure investigations may allow more detailed
characterization.3.7. Post licensure requirements
An inherent disadvantage of an approach based on a substitute
endpoint relates to the imprecise characterization of the individual
and public health impact of the vaccine, better estimated through
direct evidence generated in a large double blind randomized con-
trolled trial. In the absence of such evidence pre-licensure, impact
estimates must rely on mathematical models prone to imperfect
assumptions.
In such a context, regulators are likely to consider sero-
correlate-based indirect evidence of protection only in the context
of agreed post-approval studies for further evaluation of effective-
ness and impact. Licensure may be conditional, subject to review
after the conduct of such studies. Policy makers would also likely
require studies to assess effectiveness and impact before advising
in favour of prioritizing resources for large-scale implementation.
Post-licensure studies offer the possibility to further assess the
public health impact of the vaccine, including its preventive role
against less common endpoints, such as mortality or multi-
factorial syndromes like prematurity. Such studies may include
cluster-randomised trials, stepped-wedge designs for vaccine
introduction, case-control studies or ecological studies monitoring
changes in population disease burden. They may be linked to eval-
uations of vaccine programme implementation feasibility, as these
are increasingly seen as necessary on the pathway to vaccine avail-
ability, especially in resource-limiting settings with frail health
systems, where deployment of new interventions is most challeng-
ing, and where competition for scarce resources is most prevalent
[51,52]. Early planning and upfront identification of financing
mechanisms for pilot implementation and post-licensure evidence
generation should be identified, to avoid unnecessary delays in
access to life-saving interventions in the populations most in need.4. Conclusions
There is an urgent need for new tools to prevent the morbidity
and mortality associated with GBS disease, and GBS vaccine devel-
opment is a leading priority for protection of early life. While ran-
domized controlled clinical efficacy trials constitute the gold
standard for evidence generation, there are significant obstacles
to conducting such trials to assess efficacy against GBS invasive
disease.Please cite this article as: J. Vekemans, J. Crofts, C. J. Baker et al., The role of im
and use of group B Streptococcus vaccines for maternal immunization: consider
org/10.1016/j.vaccine.2019.04.039Alternative strategies to accelerate licensure of candidate vacci-
nes must be explored, including efforts to define serological corre-
lates of protection as acceptable substitute endpoints, derived from
studies of immunity resulting from natural exposure. Existing evi-
dence suggest this may be a viable approach. Vaccine development
sponsors, advised by regulators and policy makers, will need to
decide on their preferred vaccine development pathway for licen-
sure and policy decisions, through a careful analysis of risks and
opportunities. Multiple stakeholders should be engaged early to
promote strategic alignment and agree prospectively on method-
ological preferences, data package requirements and success crite-
ria, tackling priority activities outlined in Table 2.
Any evaluative approach is likely to include important assump-
tions and gaps. For instance, it will be hard to generate evidence
about less common serotypes. Sources of geographical hetero-
geneities should be considered. A global strategy should be devel-
oped, and similar studies should be undertaken in high-, low- and
middle-income country settings. Protective thresholds may differ
according to local epidemiology and host and pathogen factors.
From an early stage in vaccine development, regulators and pol-
icy makers should work with sponsors on possible vaccine devel-
opment pathways. A pathway involving regulatory decision-
making based on indirect evidence of clinical impact will require
post-licensure confirmation of public health benefits associated
with vaccine use in large populations, possibly during a pilot
implementation stage. Early planning of confirmatory evaluation
according to agreed methodologies, with identified financing, will
be key to reduce delays to wide-scale use, including in low
resource settings.Acknowledgements
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